Panthera Biopartners is roaring with pride after becoming the first British clinical trial organization to join Parexel’s ...

After spying blockbuster potential in Longboard Pharmaceuticals’ epilepsy med, brain disease-focused pharma Lundbeck is ...

Eli Lilly’s Gateway Labs is going global, with the U.K. government announcing today that the nation will host the first ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been ...

Jasper Therapeutics has reported complete responses in 10 of the 12 chronic hives patients who received the high dose of its ...

CMR Surgical obtained a de novo clearance from the FDA for its Versius surgical system, finally allowing its modular, ...

Transgene’s therapeutic vaccine candidate TG4001 has flunked a phase 2 solid tumor trial. But, while the prospect failed to ...

Novartis has terminated a phase 2 trial of its SMURF1 inhibitor LTP001 in idiopathic pulmonary fibrosis (IPF) but will ...

By Jula Inrig, M.D. Chief Medical Officer, Travere Therapeutics | When a specialized field of medicine has long been quiet, a ...

Authors:Kirk Harmon, Vice President & GM, Contract Sales Organization, IQVIAJavier “Jave” Castillo, R.Ph, Vice President, CSO ...

In a year that has seen an approval and a raft of readouts for metabolic dysfunction-associated steatohepatitis (MASH), ...

Difficult. Impossible. Agonizing. Worse than voting in the national election. | Difficult. Impossible. Agonizing. Worse than ...